Independent Franchise Partners LLP Reduces Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Independent Franchise Partners LLP lessened its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,617,749 shares of the company's stock after selling 246,013 shares during the period. Kenvue comprises 0.6% of Independent Franchise Partners LLP's investment portfolio, making the stock its 24th biggest holding. Independent Franchise Partners LLP owned 0.19% of Kenvue worth $77,239,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Grove Bank & Trust boosted its stake in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Kenvue during the fourth quarter worth $29,000. SRS Capital Advisors Inc. boosted its position in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after purchasing an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Remove Ads

Kenvue Trading Up 1.1 %

Shares of KVUE stock traded up $0.25 during trading hours on Tuesday, reaching $22.96. 22,262,776 shares of the stock were exchanged, compared to its average volume of 16,951,726. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $43.87 billion, a price-to-earnings ratio of 43.31, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company's 50-day moving average price is $22.75 and its 200-day moving average price is $22.40.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.57%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Redburn Atlantic assumed coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective on the stock. Citigroup upped their price objective on shares of Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a report on Monday. Barclays reduced their price target on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday. UBS Group decreased their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Finally, Canaccord Genuity Group lifted their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.